The performance of companies tied to Sildenafil's legacy presents a challenging investment picture . While the initial surge generated substantial profits , generic copies have significantly impacted revenue. Investing in related pharmaceutical companies now requires a discerning assessment of intellectual property rights , evolving patient shifts